Nikki Daskalakis

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias

Min Chul Kwon, Jan Willem Thuring, Olivier Querolle et al. · Blood · 2024 · 59 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +4

A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed/Refractory Acute Leukemia Harboring <i>KMT2A</i> or <i>NPM1</i> Alterations

Elias Jabbour, Emma Searle, Maher Abdul‐Hay et al. · Blood · 2023 · 49 citations

Medicine, Oncology, Pharmacotherapy +11

<scp>First‐in‐human</scp> study of <scp>JNJ</scp>‐63709178, a <scp>CD123</scp>/<scp>CD3</scp> targeting antibody, in relapsed/refractory acute myeloid leukemia

Michael Boyiadzis, Pinkal Desai, Nikki Daskalakis et al. · Clinical and Translational Science · 2022 · 32 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Bleximenib Dose Optimization and Determination of RP2D from a Phase 1 Study in Relapsed/Refractory Acute Leukemia Patients with <i>KMT2A</i> and <i>NPM1</i> Alterations

Emma Searle, Christian Récher, Maher Abdul‐Hay et al. · Blood · 2024 · 31 citations

Medicine, Pharmacokinetics, Pharmacology +12

First‐in‐human study of <scp>JNJ</scp>‐67571244, a <scp>CD33</scp> × <scp>CD3</scp> bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome

Rupa Narayan, Ana Alfonso Piérola, William B. Donnellan et al. · Clinical and Translational Science · 2024 · 27 citations · Full text

Medicine, Hematology, Oncology +17